Abingdon Health PLC Notice of Annual General Meeting (0114U)
2023年11月22日 - 4:00PM
RNSを含む英国規制内ニュース (英語)
TIDMABDX
RNS Number : 0114U
Abingdon Health PLC
22 November 2023
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
Notice of Annual General Meeting
York, U.K. 22 November 2023: Abingdon Health plc (AIM: ABDX), a
leading international developer and manufacturer of high quality,
rapid diagnostic tests, announces that its Annual General Meeting
('AGM') will be held on Friday 15 December 2023 at 9.30 a.m. at the
offices of Abingdon Health, York Biotech Campus, Sand Hutton, York,
YO41 1LZ, United Kingdom.
The notice convening the AGM will be sent to shareholders today
and is available on the Company's website www.abingdonhealth.com
.
Enquiries:
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer Via Walbrook PR
Chris Hand, Non-Executive Chairman
Singer Capital Markets (Sole Broker and Tel: +44 (0)20 7496 3000
Nominated Adviser)
Peter Steel, Alex Bond, Jalini Kalaravy
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or
abingdon@walbrookpr.com
Paul McManus +44 (0)7980 541 893
Phillip Marriage +44 (0)7867 984 082
Alice Woodings +44 (0)7407 804 654
About Abingdon Health plc
Abingdon Health is a leading lateral flow contract development
and manufacturing organisation ("CDMO") offering its services to an
international customer base across industry sectors that include
clinical, animal health, plant health, and environmental testing.
Abingdon Health has the internal capabilities to take projects from
initial concept through to routine and large-scale manufacturing;
from "idea to commercial success."
The Company's CDMO division offers product development,
regulatory support, technology transfer and manufacturing services
for customers looking to develop new assays or transfer existing
laboratory-based assays to a lateral flow format. Abingdon Health
aims to support the increase in need for rapid results across many
industries and locations and produces lateral flow tests in areas
such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes.
Abingdon Health's Abingdon Simply Test range of self-tests is an
ecommerce platform that offers a range of self-tests to empowers
consumers to manage their own health and wellbeing. The Abingdon
Simply Test ecommerce site offers consumers a range of information
to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract
services customers with a potential route to market for self-tests.
The Abingdon Simply Test range is also sold through international
distributors and through other channels in the UK and Ireland such
as pharmacy chains.
Founded in 2008, Abingdon Health is headquartered in York,
England.
For more information visit: www.abingdonhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAURSAROVUAUAA
(END) Dow Jones Newswires
November 22, 2023 02:00 ET (07:00 GMT)
Abingdon Health (LSE:ABDX)
過去 株価チャート
から 5 2024 まで 6 2024
Abingdon Health (LSE:ABDX)
過去 株価チャート
から 6 2023 まで 6 2024